The spectrum of hepatic functional impairment in compensated chronic hepatitis C: Results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 9, 2008, Pages 798-809

  Everson, G T ^a,h   Shiffman, M L ^b   Morgan, T R ^c,d   Hoefs, J C ^c,d   Sterling, R K ^b   Wagner, D A ^e   Kulig, C C ^a   Curto, T M ^f   Wright, E C ^g  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^e METABOLIC SOLUTIONS INC   (United States)

^f NEW ENGLAND RESEARCH INSTITUTES   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHOLIC ACID; GALACTOSE; LIDOCAINE; METHIONINE; PHENAZONE; SULFUR;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HEPATITIS C; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER CYTOSOL; LIVER FIBROSIS; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER MICROSOME; LIVER MITOCHONDRION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PORTAL VEIN BLOOD FLOW; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; VARICOSIS;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; STATISTICS AS TOPIC;

EID: 41749098568     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03639.x     Document Type: Article

References (25)

1. Fontana RJ, Lok ASF. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002 36 : S57 64.
2. Lotterer E, Hogel J, Gaus W, Fleig W, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology 1997 26 : 6.
3. Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995 15 : 3.
4. Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997 22 : 237 49.
5. Figg W, Dukes G, Lesesne H, et al. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 1995 15 : 6.
6. Everson GT, Martucci MA, Shiffman ML, et al. Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007 26 : 401 10.
7. Hoefs JC, Wang F, Kanel G, Braunstein P. The liver-spleen scan as a quantitative liver function test: correlation with liver severity at peritoneoscopy. Hepatology 1995 22 : 1113 21.
8. Hoefs JC, Wang F, Kanel G. Functional measurement of the non-fibrotic hepatic mass in cirrhotic patient. Am J Gastroenterol 1997 92 : 2054 8.
9. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 25 : 472 92.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 9.
11. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999 94 : 2467 74.
12. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York, NY : John Wiley and Sons, 2000.
13. SAS Institute, Inc., SAS/STAT® 9.1 User's Guide, Cary, NC : SAS Institute, Inc., 2004.
14. Rosner B. Fundamentals of Biostatistics, 3rd edn. Belmont, CA : Duxbury Press, 1990.
15. Hoefs J, Chang K, Wang F, Kanel G, Morgan T, Braunstein P. The perfused Kupffer cell mass: correlation with histology and severity of CLD. Dig Dis Sci 1995 40 : 552 60.
16. Hoefs JC, Wang F, Lilien D, Walker B, Kanel B. A novel, simple method of functional spleen volume calculation by liver-spleen scan. J Nucl Med 1999 40 : 1745 55.
17. Shrestha R, McKinley C, Showalter R, et al. Quantitative Liver Function Tests (QLFTs) define the functional severity of liver disease in early stage cirrhosis. Liver Transpl Surg 1997 3 : 166 73.
18. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 57.
19. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007 133 : 481 8.
20. Samonakis DN, Cholonngitas E, Thalheimer U, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007 13 : 1305 11.
21. Trotter JF, Osborne JC, Heller M, Christian U. Effect of hepatitis C infection on tacrolimus dose and blood levels in liver transplant recipients. Aliment Pharmacol Ther 2005 22 : 37 44.
22. Wolffenbuttel L, Poli DD, Manfro RC, Goncalves LF. Cyclosporine pharmacokinetics in HCV+ patients. Clin Transplant 2004 18 : 654 60.
23. Robertson SM, Scarsi KK, Postelnick MJ, Lynch P. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review. Pharmacotherapy 2005 25 : 1068 72.
24. Kugelmas M, Osgood M, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejections. Liver Transpl 2003 9 : 1159 65.
25. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002 16 : 185 94.